title: [Pathogenetic correction of postoperative inflammation in modern rhinosurgery].
abstract: This study included 20 patients presenting with polypous rhinosinusitis examined before and after endoscopic intervention in the nasal cavity and paranasal sinuses. Nitric oxide (NO) content in nasal secretion and polypoid tissue was estimated from the concentration of nitrates that, together with nitrites, are the final products of oxidation of nitric oxide and serve as markers of endogenous NO. Nitrates in the nasal secretion, endonasal mucosa, and polypous tissue were determined by the ionometric technique. Their content was additionally measured in 12 subjects without polypous rhinosinusitis. The nasal secretion and polypous tissue of PRS patients were found to contain nitrates at a higher concentration compared with healthy subjects. Nitrate concentrations in the nasal secretion and polypous tissue of PRS patients were not significantly different. Mean saccharine transport time in the nasal cavity of the patients with an elevated level of nitrates in the nasal secretion was significantly higher than in PRS patients with the lowered nitrate levels. It means that high concentrations of nitric oxide markers in the nasal secretion and polypous tissue of the patients with polypous rhinosinusitis have negative effect on the efficiency of mucociliary transport. In addition, results of the study confirm the possibility of anti-inflammatory therapy with Erespal (fenspirid) for the correction of inflammatory changes during the postoperative period.
authors.forename: I A
authors.initials: IA
authors.lastname: Kim
authors.forename: E V
authors.initials: EV
authors.lastname: Nosulia
mesh_terms: D015415:Biomarkers / Q000032:analysis / Q000378:metabolism; D004724:Endoscopy; D006801:Humans; D009079:Mucociliary Clearance; D009298:Nasal Polyps / Q000188:drug therapy / Q000378:metabolism / Q000628:therapy*; D009569:Nitric Oxide / Q000032:analysis / Q000378:metabolism*; D011184:Postoperative Period; D012220:Rhinitis / Q000188:drug therapy / Q000378:metabolism / Q000601:surgery*; D012852:Sinusitis / Q000188:drug therapy / Q000378:metabolism / Q000601:surgery*; D013141:Spiro Compounds / Q000627:therapeutic use
chemical_list: D015415:Biomarkers; D013141:Spiro Compounds; D009569:Nitric Oxide; C084775:fenspiride